time

[키워드] 95% confidence interval Adjusted analysis Administered Admission age alcohol allocation concealment ALT/AST Analysis Arm arrhythmia assigned Beta block-randomization Blood calculated Care center clinical Clinical improvement clinical trial conducted confirmed case control group cough COVID-19 COVID-19 confirmed patient COVID-19 in patient COVID-2019 Cox proportional-hazards model death discharge disease dissemination drug Duration education Effectiveness element eligibility enrolled excluded exclusion criteria fatigue follow-up time hazard headache Health hospital hospital discharge Hospitalization Hydroxychloroquine + Lopinavir/Ritonavir improvement include Interaction Interferon beta-1a Interferon-β 1a Interferon-β 1b intervals intervention group investigator Kaletra Kaplan–Meier laboratory result lactating women Last limit log-rank test Loghman Hakim Hospital Lopinavir Lopinavir/ritonavir masking mechanical ventilation Medical Science Medical Sciences moderate Mortality myalgia nasal NCT04343768 number objective open label Open-label Other outcome oxygen saturation package parallel group participant Patient performed positive pregnant Primary outcome primary outcome measure problem professional protocol pulse-oximetry R software R version 3.6.1 randomization randomization sequence Randomized Randomized controlled trial Randomly reached receive Recigen recruitment refusal regimen Registered Research respiratory rate RT-PCR test Sample SARS-CoV-2 sealed secondary secondary outcome seven-category ordinal scale single center single dose SpO2 sputum production standard care status Study protocol Symptom temperature tested the patient therapeutic three groups time treat treated treatment groups Trial university version 3.6.1 website World Health Organization Ziferon
[DOI] 10.1186/s13063-020-04382-3 PMC 바로가기 [Article Type] Letter